172 related articles for article (PubMed ID: 35203384)
1. A Transcriptional Link between HER2, JAM-A and FOXA1 in Breast Cancer.
Cruz RGB; Madden SF; Brennan K; Hopkins AM
Cells; 2022 Feb; 11(4):. PubMed ID: 35203384
[TBL] [Abstract][Full Text] [Related]
2. Human Epidermal Growth Factor Receptor-3 Expression Is Regulated at Transcriptional Level in Breast Cancer Settings by Junctional Adhesion Molecule-A via a Pathway Involving Beta-Catenin and FOXA1.
Cruz RGB; Madden SF; Richards CE; Vellanki SH; Jahns H; Hudson L; Fay J; O'Farrell N; Sheehan K; Jirström K; Brennan K; Hopkins AM
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33669586
[TBL] [Abstract][Full Text] [Related]
3. Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
Leech AO; Vellanki SH; Rutherford EJ; Keogh A; Jahns H; Hudson L; O'Donovan N; Sabri S; Abdulkarim B; Sheehan KM; Kay EW; Young LS; Hill ADK; Smith YE; Hopkins AM
Breast Cancer Res; 2018 Nov; 20(1):140. PubMed ID: 30458861
[TBL] [Abstract][Full Text] [Related]
4. Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling.
Brennan K; McSherry EA; Hudson L; Kay EW; Hill AD; Young LS; Hopkins AM
Oncogene; 2013 May; 32(22):2799-804. PubMed ID: 22751120
[TBL] [Abstract][Full Text] [Related]
5. Natural compound Tetrocarcin-A downregulates Junctional Adhesion Molecule-A in conjunction with HER2 and inhibitor of apoptosis proteins and inhibits tumor cell growth.
Vellanki SH; Cruz RGB; Jahns H; Hudson L; Sette G; Eramo A; Hopkins AM
Cancer Lett; 2019 Jan; 440-441():23-34. PubMed ID: 30312728
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor-β1 attenuates junctional adhesion molecule-A and contributes to breast cancer cell invasion.
Wang Y; Lui WY
Eur J Cancer; 2012 Dec; 48(18):3475-87. PubMed ID: 22647687
[TBL] [Abstract][Full Text] [Related]
7. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer cell migration is regulated through junctional adhesion molecule-A-mediated activation of Rap1 GTPase.
McSherry EA; Brennan K; Hudson L; Hill AD; Hopkins AM
Breast Cancer Res; 2011 Mar; 13(2):R31. PubMed ID: 21429211
[TBL] [Abstract][Full Text] [Related]
9. Abrogation of junctional adhesion molecule-A expression induces cell apoptosis and reduces breast cancer progression.
Murakami M; Giampietro C; Giannotta M; Corada M; Torselli I; Orsenigo F; Cocito A; d'Ario G; Mazzarol G; Confalonieri S; Di Fiore PP; Dejana E
PLoS One; 2011; 6(6):e21242. PubMed ID: 21695058
[TBL] [Abstract][Full Text] [Related]
10. Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases.
Horimoto Y; Arakawa A; Harada-Shoji N; Sonoue H; Yoshida Y; Himuro T; Igari F; Tokuda E; Mamat O; Tanabe M; Hino O; Saito M
Br J Cancer; 2015 Jan; 112(2):345-51. PubMed ID: 25422910
[TBL] [Abstract][Full Text] [Related]
11. Identification of lineage-specific epigenetic regulators FOXA1 and GRHL2 through chromatin accessibility profiling in breast cancer cell lines.
Yang L; Kumegawa K; Saeki S; Nakadai T; Maruyama R
Cancer Gene Ther; 2024 May; 31(5):736-745. PubMed ID: 38429368
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of junctional adhesion molecule-A is a contributing factor for breast cancer cell invasion.
Naik MU; Naik TU; Suckow AT; Duncan MK; Naik UP
Cancer Res; 2008 Apr; 68(7):2194-203. PubMed ID: 18381425
[TBL] [Abstract][Full Text] [Related]
14. High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer.
Horimoto Y; Sasahara N; Sasaki R; Hlaing MT; Sakaguchi A; Saeki H; Arakawa A; Himuro T; Saito M
Breast Cancer Res Treat; 2020 Aug; 183(1):41-48. PubMed ID: 32572714
[TBL] [Abstract][Full Text] [Related]
15. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
16. Development of a Novel Weighted Ranking Method for Immunohistochemical Quantification of a Heterogeneously Expressed Protein in Gastro-Esophageal Cancers.
Richards CE; Sheehan KM; Kay EW; Hedner C; Borg D; Fay J; O'Grady A; Hill ADK; Jirström K; Hopkins AM
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33805812
[TBL] [Abstract][Full Text] [Related]
17. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
[TBL] [Abstract][Full Text] [Related]
18. Cell lineage tracing links ERα loss in Erbb2-positive breast cancers to the arising of a highly aggressive breast cancer subtype.
Ding Y; Liu Y; Lee DK; Tong Z; Yu X; Li Y; Xu Y; Lanz RB; O'Malley BW; Xu J
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34006643
[TBL] [Abstract][Full Text] [Related]
19. JAM-A Acts via C/EBP-α to Promote Claudin-5 Expression and Enhance Endothelial Barrier Function.
Kakogiannos N; Ferrari L; Giampietro C; Scalise AA; Maderna C; Ravà M; Taddei A; Lampugnani MG; Pisati F; Malinverno M; Martini E; Costa I; Lupia M; Cavallaro U; Beznoussenko GV; Mironov AA; Fernandes B; Rudini N; Dejana E; Giannotta M
Circ Res; 2020 Sep; 127(8):1056-1073. PubMed ID: 32673519
[TBL] [Abstract][Full Text] [Related]
20. FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer.
Gong C; Fujino K; Monteiro LJ; Gomes AR; Drost R; Davidson-Smith H; Takeda S; Khoo US; Jonkers J; Sproul D; Lam EW
Oncogene; 2015 Sep; 34(39):5012-24. PubMed ID: 25531315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
